tiprankstipranks
Trending News
More News >
Arcellx Inc (ACLX)
NASDAQ:ACLX
US Market

Arcellx Inc (ACLX) AI Stock Analysis

Compare
231 Followers

Top Page

AC

Arcellx Inc

(NASDAQ:ACLX)

Rating:55Neutral
Price Target:
$67.00
▲(4.82%Upside)
Arcellx Inc's stock score reflects a mix of financial challenges and promising corporate developments. While financial performance and valuation are pressured by ongoing losses, positive clinical trial results and strategic board changes offer potential upside. Technical signals suggest a neutral market sentiment.
Positive Factors
Efficacy Data
The treatment achieved high rates of MRD negativity at 93.3%, indicating strong treatment efficacy.
Regulatory Prospects
The probability of accelerated approval based on iMMagine-1 outcomes in 2026 is considered very high by analysts, given the excellent benefit/harm demonstrated in the study.
Safety Profile
Anito-cel's safety profile shows no delayed or non-immune effector cell-associated neurotoxicity syndrome (ICANS) neurotoxicities, including no Parkinsonism, no cranial nerve palsies, and no Guillain-Barré syndrome.
Negative Factors
Market Reaction
ACLX is volatile but trending down on the news, possibly due to misinterpretation of the press release.
Perception of Catalysts
Investors may perceive a lack of near-term catalysts since the press release provided the most important data updates expected at the European Hematology Association meeting.
Regulatory Environment
Stock reaction may be tied to a recent overhang on multiple myeloma cell therapy development and prospects in earlier-line treatment due to public comments by a newly announced CBER director.

Arcellx Inc (ACLX) vs. SPDR S&P 500 ETF (SPY)

Arcellx Inc Business Overview & Revenue Model

Company DescriptionArcellx Inc (ACLX) is a biotechnology company focused on developing innovative cell therapies for cancer and other serious diseases. The company is involved in the research and development of proprietary cell therapy platforms designed to enhance the safety, efficacy, and accessibility of these treatments. Arcellx's core product offerings revolve around its proprietary ARC-SparX platform, which aims to improve the precision and flexibility of cell therapies.
How the Company Makes MoneyArcellx Inc makes money primarily through the development and commercialization of its cell therapy products. The company's revenue model is centered around advancing its proprietary ARC-SparX platform through clinical trials, gaining regulatory approvals, and eventually bringing these therapies to market. Key revenue streams include potential milestone payments and royalties from partnerships with other biotechnology and pharmaceutical companies. Additionally, Arcellx may engage in strategic collaborations or licensing agreements, which can provide upfront payments and ongoing financial support as the therapies progress through various stages of development.

Arcellx Inc Financial Statement Overview

Summary
Arcellx Inc faces significant challenges in achieving profitability and maintaining financial health. The company has no revenue in 2024, zero stockholders' equity, and negative cash flow, despite efforts to reduce liabilities. These factors raise concerns about the company's financial stability.
Income Statement
30
Negative
Arcellx Inc has struggled with profitability, as evidenced by consistent net losses over the years. The absence of revenue in 2024 highlights a concerning trend in revenue generation. The company managed to achieve revenue in 2023, which was a bright spot, but it is not sustained in 2024. Gross profit margins and other profitability metrics are negative due to the lack of revenue and high operating costs, indicating persistent challenges in achieving financial stability.
Balance Sheet
40
Negative
The balance sheet shows a concerning trend with zero stockholders' equity in 2024, indicating potential financial distress. The total assets have sharply declined, and the company now has no debt, which is a positive aspect. However, the lack of equity presents a significant risk. In previous years, the company had significant liabilities, which have now been reduced to zero, suggesting an effort to deleverage.
Cash Flow
50
Neutral
The company's cash flow situation is mixed. Operating cash flow has turned negative in 2024 after a positive year in 2023. There is a significant decline in free cash flow, reflecting challenges in generating cash from operations. The reduction in capital expenditures is a positive sign, indicating a more cautious approach to spending, but the overall negative cash flow trend could be concerning if it continues.
Breakdown
Dec 2024Dec 2023Dec 2022Dec 2021Dec 2020
Income StatementTotal Revenue
107.94M110.32M0.000.000.00
Gross Profit
107.94M110.32M-2.22M-1.04M-629.00K
EBIT
-137.57M-89.88M-191.26M-65.02M-32.10M
EBITDA
-99.06M-64.14M-184.74M-63.93M-31.47M
Net Income Common Stockholders
-107.35M-70.69M-186.10M-63.93M-32.09M
Balance SheetCash, Cash Equivalents and Short-Term Investments
587.38M702.02M254.84M104.62M46.60M
Total Assets
711.33M825.13M313.82M128.78M57.69M
Total Debt
54.08M97.63M88.13M100.00K0.00
Net Debt
-51.60M-296.96M23.95M-104.52M-46.60M
Total Liabilities
256.54M339.75M108.86M250.30M121.41M
Stockholders Equity
454.79M485.38M204.95M-121.52M-63.72M
Cash FlowFree Cash Flow
-96.90M186.15M-101.58M-60.02M-29.55M
Operating Cash Flow
-83.47M207.57M-99.30M-54.24M-28.66M
Investing Cash Flow
-183.04M-154.51M-117.67M-79.98M-888.00K
Financing Cash Flow
-24.09M279.16M252.63M118.45M41.66M

Arcellx Inc Technical Analysis

Technical Analysis Sentiment
Neutral
Last Price63.92
Price Trends
50DMA
62.89
Negative
100DMA
65.14
Negative
200DMA
73.16
Negative
Market Momentum
MACD
0.11
Negative
RSI
51.07
Neutral
STOCH
63.35
Neutral
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For ACLX, the sentiment is Neutral. The current price of 63.92 is above the 20-day moving average (MA) of 60.73, above the 50-day MA of 62.89, and below the 200-day MA of 73.16, indicating a neutral trend. The MACD of 0.11 indicates Negative momentum. The RSI at 51.07 is Neutral, neither overbought nor oversold. The STOCH value of 63.35 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Neutral sentiment for ACLX.

Arcellx Inc Risk Analysis

Arcellx Inc disclosed 80 risk factors in its most recent earnings report. Arcellx Inc reported the most risks in the “Tech & Innovation” category.
Finance & Corporate - Financial and accounting risks. Risks related to the execution of corporate activity and strategy
Latest Risks Added 2 New Risks
1.
Gilead holds 6,720,803 shares, or approximately 13%, of our outstanding shares of common stock which are restricted from immediate resale pursuant to the terms of the Amended Standstill Agreement but may be sold into the market in the near future. Such resale could cause the market price of our common stock to drop significantly, even if our business is doing well. Q4, 2024
2.
Inadequate funding for the FDA, the SEC and other government agencies could hinder their ability to hire and retain key leadership and other personnel, prevent new products and services from being developed or commercialized in a timely manner or otherwise prevent those agencies from performing normal business functions on which the operation of our business may rely, which could negatively impact our business. Q4, 2024

Arcellx Inc Peers Comparison

Overall Rating
UnderperformOutperform
Sector (53)
Financial Indicators
Name
Overall Rating
Market Cap
P/E Ratio
ROE
Dividend Yield
Revenue Growth
EPS Growth
69
Neutral
$3.64B7.0533.08%91.12%
55
Neutral
$3.52B-35.56%-41.66%-180.15%
54
Neutral
$3.50B-51.57%730.42%31.63%
53
Neutral
$5.14B3.23-45.01%2.85%17.55%-0.69%
52
Neutral
$3.97B-418.97%48.88%39.30%
48
Neutral
$2.83B60.028.99%-34.02%-65.83%
43
Neutral
$3.32B-386.33%33.46%26.72%
* Healthcare Sector Average
Performance Comparison
Ticker
Company Name
Price
Change
% Change
ACLX
Arcellx Inc
61.95
10.65
20.76%
PTCT
PTC Therapeutics
47.86
11.39
31.23%
RARE
Ultragenyx Pharmaceutical
35.08
-4.26
-10.83%
PTGX
Protagonist Therapeutics
46.43
16.45
54.87%
RYTM
Rhythm Pharmaceuticals
59.18
22.97
63.44%
SWTX
Springworks Therapeutics
46.46
4.15
9.81%

Arcellx Inc Corporate Events

Product-Related AnnouncementsBusiness Operations and Strategy
Arcellx Announces Positive Phase 2 Study Results
Positive
May 14, 2025

On May 14, 2025, Arcellx, Inc. announced positive results from its Phase 2 pivotal iMMagine-1 study of anitocabtagene autoleucel (anito-cel) for patients with relapsed or refractory multiple myeloma. The study demonstrated a 97% overall response rate and a 68% complete response rate, with no delayed neurotoxicities observed. These findings will be presented at the EHA 2025 Congress, highlighting the potential of anito-cel to address unmet needs in multiple myeloma treatment. The company, in collaboration with Kite, plans to commercialize anito-cel, with a 2026 launch anticipated.

The most recent analyst rating on (ACLX) stock is a Buy with a $85.00 price target. To see the full list of analyst forecasts on Arcellx Inc stock, see the ACLX Stock Forecast page.

Executive/Board ChangesBusiness Operations and Strategy
Arcellx Inc Announces Board Changes for Strategic Growth
Positive
Mar 20, 2025

On March 18, 2025, Arcellx, Inc. announced changes to its Board of Directors, with Derek Yoon resigning and Andrew Galligan and Kristin Myers being appointed to fill vacancies. These appointments bring significant experience to the company, with Galligan’s financial leadership and Myers’ healthcare expertise expected to support Arcellx’s strategic growth and anticipated commercial launch of its lead product candidate, anito-cel, in 2026.

Glossary
OutperformA stock rated as "Outperform" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests that the stock is likely to deliver higher returns compared to the average returns of other stocks in the same sector or market index. Investors might consider this stock a good buying opportunity.
NeutralA stock rated as "Neutral" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly attractive nor unattractive for investment. Investors may consider holding onto the stock, as it is not expected to either significantly outperform or underperform the market.
UnderperformA stock rated as "Underperform" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests that the stock may deliver lower returns compared to the average returns of other stocks in the same sector or market index. Investors might consider selling the stock or avoiding it as an investment.

Disclaimer

This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.